Two oncology floats to end the summer break
Bicara and DualityBio will soon test market appetite for new oncology issues.
A Prelude to a Lilly duel
The leading proponents of selective SMARCA2 inhibition are taking their oral projects into clinical trials.
Toxicity hits BioNTech’s MediLink tie-up
A mysterious ASCO poster, patient deaths and now clinical hold; where next for BioNTech’s ADC deal?
We haven't lost focus, BioNTech insists
The company defends its cancer strategy, and says it's not a me-too developer.
